6,607 results match your criteria Journal of Thrombosis and Haemostasis[Journal]


The American College of Chest Physicians score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: more.

Authors:
Clive Kearon

J Thromb Haemost 2019 Apr 25. Epub 2019 Apr 25.

Department of Medicine, McMaster University, Hamilton, ON, Canada.

Palareti and colleagues recently published findings from the START2 registry in which they assessed validity of the American College of Chest Physicians' (ACCP) approach to stratifying risk of major bleeding during long-term anticoagulation (hereafter referred to as the "ACCP tool"). They concluded that the ACCP tool was not valid and should not be used to guide decisions about long-term anticoagulation in patients with venous thromboembolism (VTE). In correspondence arising from their publication, they reiterated their criticisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14459DOI Listing
April 2019
1 Read

Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders.

J Thromb Haemost 2019 Apr 25. Epub 2019 Apr 25.

Department of Haematology and Central Haematology Laboratory, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Background: Bleeding assessment tools (BAT) have been widely implemented in the work-up of patients with suspected bleeding disorders. However, diagnostic BAT utility regarding platelet function disorders is still elusive.

Aim: We aimed to assess the diagnostic value of the International Society on Thrombosis and Haemostasis BAT (ISTH-BAT) for platelet function disorders in clinical practice. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14454
Publisher Site
http://dx.doi.org/10.1111/jth.14454DOI Listing
April 2019
1 Read

Severe haemophilia A caused by an unbalanced chromosomal rearrangement identified using nanopore sequencing.

J Thromb Haemost 2019 Apr 25. Epub 2019 Apr 25.

Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'hématologie Biologique, Bron, France.

Background: No F8 genetic abnormality is detected in about 2% of severe haemophilia A patients using conventional genetic approaches. In these patients, deep intronic variation or F8 disrupting genomic rearrangement could be causal.

Objective: To characterize, in a genetically unresolved severe haemophilia A patient, a new Xq28 rearrangement disrupting F8 using comprehensive molecular techniques including nanopore sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14460DOI Listing

Effectiveness and Safety of Thromboprophylaxis with Enoxaparin for Prevention of Pregnancy-Associated Venous Thromboembolism.

J Thromb Haemost 2019 Apr 23. Epub 2019 Apr 23.

National Women's Health, Auckland City Hospital, Auckland.

Background: Low-molecular weight heparin (LMWH) is used to prevent pregnancy-associated venous thromboembolism (PA-VTE) but there are limited data to inform which women require thromboprophylaxis in pregnancy and debate about which LMWH dose is effective and safe.

Aims: To evaluate the efficacy and rate of complications using enoxaparin for thromboprophylaxis in a cohort of women at risk of PA-VTE managed between 1999 and 2014 at National Women's Hospital, a tertiary obstetric referral centre in Auckland, New Zealand.

Methods: A retrospective, observational study of women who received thromboprophylaxis with enoxaparin for prevention of PA-VTE while under the care of the obstetric or maternal fetal medicine team. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14452DOI Listing

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.

J Thromb Haemost 2019 Apr 23. Epub 2019 Apr 23.

Arianna Anticoagulazione Foundation, Bologna, Italy.

Background: Direct oral anticoagulants (DOACs) are administered at fixed dose. Aim of the study was to evaluate the relationship between DOAC C-trough or C-peak plasma levels, and bleeding complications in patients with non-valvular atrial fibrillation (NVAF).

Methods: 565 consecutive naive NVAF patients were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14457DOI Listing
April 2019
1 Read

Exon 2 Skipping Eliminates Gamma-Glutamyl Carboxylase Activity, Indicating a Partial Splicing Defect in a Patient with Vitamin K Clotting Factor Deficiency.

J Thromb Haemost 2019 Apr 22. Epub 2019 Apr 22.

Departments of Cardiovascular, Lerner Research Institute, Cleveland Clinic Lerner College of Medicine at CWRU, Cleveland Clinic, 9500 Euclid Avenue NB50, Cleveland, OH, 44195.

Background: Mutations in the gamma-glutamyl carboxylase (GGCX), which is required for vitamin K-dependent (VKD) protein activation, can result in vitamin K clotting factor deficiency (VKCFD1). A recent report described a VKCFD1 patient with a homozygous carboxylase mutation that altered splicing and deleted exon 2 (Δ2GGCX). Only Δ2GGCX RNA was observed in the patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14456DOI Listing

Follow-up to Response on "Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: Systematic Review and Meta-Analysis".

J Thromb Haemost 2019 Apr 22. Epub 2019 Apr 22.

Winship Cancer Institute of Emory University, Atlanta, GA, USA.

We would like to thank Dufrost and colleagues for their valuable comments on our systematic review [1]. The significant risk of venous as well as arterial thrombosis among patients with the antiphospholipid syndrome (APS) is well-established, and we acknowledge the challenges of anticoagulation therapy in this patient population. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14453
Publisher Site
http://dx.doi.org/10.1111/jth.14453DOI Listing
April 2019
1 Read

Reactivity of Platelet-activating and Non-platelet-activating anti-PF4/Heparin Antibodies in Enzyme Immunosorbent Assays under different Conditions.

J Thromb Haemost 2019 Apr 22. Epub 2019 Apr 22.

Institute for Immunology and Transfusion Medicine, University Medicine of Greifswald, 17475, Greifswald, Germany.

Background: Enzyme immunosorbent assays (EIA) are widely used to detect human anti-platelet factor 4/heparin antibodies (aPF4/H Abs) to rule out heparin-induced thrombocytopenia. However, EIAs cannot differentiate between clinically relevant, platelet-activating and non-relevant, non-platelet activating Abs and only ~50% of patients' sera testing positive by EIA contain antibodies which activate platelets. Recently, we have shown platelet activating aPF4/H Abs bind more strongly to PF4/H complexes than non-platelet activating antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14455DOI Listing

Temperature-dependent irreversible conformational change of recombinant ADAMTS13 upon metal ion chelation.

J Thromb Haemost 2019 Apr 21. Epub 2019 Apr 21.

Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienna, Austria.

Background: The catalytic domain of ADAMTS13 possesses one Zn and up to three putative Ca binding sites and can be inactivated by chelating agents. Although replenishment with an appropriate metallic cation is thought to restore the enzyme's proteolytic activity fully, ADAMTS13 stability in a metal ion-depleting environment has not been explored.

Objectives: To address the stability of ADAMTS13 in citrated human plasma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14440DOI Listing

FAM-tastic phospho-regulation of von Willebrand factor activity.

J Thromb Haemost 2019 Apr 15. Epub 2019 Apr 15.

Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

A recent investigation performed by Da et al. provides evidence that von Willebrand factor (VWF) can be phosphorylated in the A2 domain, a modification that has never before been observed [1]. VWF is a multimeric glycoprotein that mediates platelet adhesion to the endothelium upon vascular injury, a process critical for hemostasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14448DOI Listing
April 2019
2 Reads

An assay to measure levels of factor Xa inhibitors in blood and plasma.

J Thromb Haemost 2019 Apr 15. Epub 2019 Apr 15.

Thrombosis and Atherosclerosis Research Institute, Hamilton, OntarioCanada.

Background: Rivaroxaban and apixaban are the most commonly used anti-factor (F) Xa direct oral anticoagulants (DOAC), with indications for prevention of stroke in non-valvular atrial fibrillation as well as treatment and prevention of venous thromboembolism. However, lacking is accessibility to a detection method that is able to quantify low levels of anti-FXa DOACs.

Objective: We report a new assay that measures anti-FXa DOACs levels in plasma and whole blood. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14451
Publisher Site
http://dx.doi.org/10.1111/jth.14451DOI Listing
April 2019
2 Reads

Physical activity and risk of recurrence and mortality after incident venous thromboembolism.

J Thromb Haemost 2019 Apr 15. Epub 2019 Apr 15.

K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT, The Arctic University of Norway, Tromsø, Norway.

Background: Limited data exist on the relationship between physical activity and major complications after incident venous thromboembolism (VTE).

Objectives: To investigate whether physical activity was associated with risk of recurrence and mortality in VTE patients recruited from the general population.

Methods: Patients with incident VTE (n=786) derived from the Tromsø Study surveys 4-6 (1994-95, 2001-02 and 2007-08) were included, and data on physical activity was dichotomized according to the activity level reported in the survey preceding the incident VTE (inactive: <1h per week, active: ≥1h per week). Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14449
Publisher Site
http://dx.doi.org/10.1111/jth.14449DOI Listing
April 2019
3 Reads

Trauma-Induced Coagulopathy: The Past, Present, and Future.

J Thromb Haemost 2019 Apr 15. Epub 2019 Apr 15.

Department of Surgery, Denver Health Medical Center and the University of Colorado, 777 Bannock Street. Mail Code 0206, Denver, CO, 80203.

Trauma remains a leading cause of death worldwide, and most early preventable deaths in both the civilian and military settings are due to uncontrolled hemorrhage, despite paradigm advances in modern trauma care. Combined tissue injury and shock result in hemostatic failure, which has been identified as a multi-dimensional molecular, physiologic, and clinical disorder termed trauma-induced coagulopathy (TIC). Understanding the biology of TIC is of utmost importance as it is often responsible for uncontrolled bleeding, organ failure, thromboembolic complications, and death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14450DOI Listing
April 2019
2 Reads

Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: a systematic review and analysis.

J Thromb Haemost 2019 Apr 4. Epub 2019 Apr 4.

Department of Surgery, University of Colorado Denver, Denver, CO, USA.

Background: Thromboelastography (TEG 5000/6s Thrombelastograph Hemostasis Analyzer; Haemonetics , Braintree, MA) is a point-of-care system designed to monitor and analyze the entire coagulation process in real time. TEG -guided therapy has been shown to be valuable in a variety of surgical settings.

Objective: While guidelines recommend viscoelastic monitoring for the management of perioperative bleeding, there are no meta-analyses specifically evaluating the effects of TEG -guided transfusion on patient outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14447DOI Listing
April 2019
13 Reads

Obesity is associated with in vivo platelet activation and impaired responsiveness to once-daily, low-dose aspirin.

J Thromb Haemost 2019 Apr 1. Epub 2019 Apr 1.

Istituto di Farmacologia, Università Cattolica, Rome, Italy.

Background: Obesity is raising worldwide, increases cardiovascular risk, modifies body composition and organ function, and potentially affects drug's pharmacokinetics and/or pharmacodynamics.

Objectives: To investigate pharmacodynamics of once-daily low-dose aspirin in healthy obese subjects and to assess whether body weight (BW) or body mass index (BMI) would affect aspirin pharmacology.

Patients/methods: Otherwise healthy, obese (BMI>30kg/m ) subjects were studied before and after 3-4 weeks of 100mg once-daily aspirin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14445DOI Listing
April 2019
2 Reads

Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia.

J Thromb Haemost 2019 Apr 1. Epub 2019 Apr 1.

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Essentials Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet count. We conducted a cohort study of 3 584 chronic ITP patients from the Nordic countries. Cardiovascular events occurred across all platelet count levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14446DOI Listing
April 2019
1 Read

Erratum.

Authors:

J Thromb Haemost 2019 Apr 14;17(4):698. Epub 2019 Mar 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14421DOI Listing

The Direct Oral Anticoagulants Rivaroxaban and Dabigatran do not Inhibit Orthotopic Growth and Metastasis of Human Breast Cancer in Mice.

J Thromb Haemost 2019 Mar 31. Epub 2019 Mar 31.

Einthoven Laboratory for Vascular and Regenerative Medicine, Div. of Thrombosis and Hemostasis, Dept. of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Background: Factor Xa (FXa)-targeting direct oral anticoagulants (DOAC) were recently found to efficiently reduce recurrent venous thromboembolism (VTE) in cancer patients when compared to the standard treatment with low-molecular-weight heparins (LMWHs). While the anti-cancer effects of LMWHs have been extensively studied in preclinical cancer models, the effects of FXa-targeting DOACs on cancer progression remain to be studied.

Objective: We investigated whether the FXa-targeting DOAC rivaroxaban and the thrombin-targeting DOAC dabigatran etexilate (DE) affected human breast cancer growth and metastasis in orthotopic xenograft models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14443DOI Listing
March 2019
3 Reads

Blood group antigen A on von Willebrand factor is more protective against ADAMTS13 cleavage than antigens B and H.

J Thromb Haemost 2019 Mar 31. Epub 2019 Mar 31.

Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan.

Background: ADAMTS13 specifically cleaves the peptide bond between Y1605 and M1606 within the von Willebrand factor (VWF)-A2 domain.

Objective: VWF contains ABO(H) blood group antigens, which may influence the susceptibility of VWF to ADAMTS13.

Methods: Using a unique monoclonal antibody recognizing the Y1605 residue, we have developed a sandwich ELISA to quantitatively analyze the generation of a VWF-degradation product (VWF-DP) by ADAMTS13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14444DOI Listing
March 2019
1 Read

Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application.

J Thromb Haemost 2019 Apr 30;17(4):699-707. Epub 2019 Mar 30.

University of Maryland.

Murine models are widely used valuable tools to study deep vein thrombosis (VT). Leading experts in VT research came together through the American Venous Forum to develop a consensus on maximizing the utility and application of available mouse models of VT. In this work, we provide an algorithm for model selection, with discussion of the advantages, disadvantages, and applications of the main mouse models of VT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14413DOI Listing
April 2019
1 Read

Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in haemophilia A rats.

J Thromb Haemost 2019 Mar 29. Epub 2019 Mar 29.

Haemophilia Research, Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark.

Background: Understanding of the pharmacokinetic (PK) interplay between factor VIII (FVIII) and von Willebrand factor (VWF) following high-dose FVIII treatment is lacking.

Objectives: To characterize the PK of recombinant FVIII (rFVIII), VWF and the rFVIII:VWF complex in haemophilia A rats following intravenous administration of rFVIII using PK modeling. A second aim was to investigate the impact of high daily dosing and constant expression of rFVIII on VWF exposure using PK simulations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14441DOI Listing
March 2019
3 Reads

Operative spinal trauma: Thromboprophylaxis with low molecular weight heparin or a direct oral anticoagulant.

J Thromb Haemost 2019 Mar 28. Epub 2019 Mar 28.

Division of Trauma, Critical Care, Emergency Surgery, and Burns, Department of Surgery, University of Arizona, Tucson, Arizona.

Essentials Operative spine trauma patients are at increased risk of venous thromboembolism (VTE). Direct oral anticoagulants (DOACs) may have a favorable efficacy and safety in spine trauma. Patients on DOACs had lower rates of VTE in comparison to low molecular weight heparin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14439DOI Listing
March 2019
1 Read

Complement Activation Assessed by the Plasma Terminal Complement Complex and Future Risk of Venous Thromboembolism.

J Thromb Haemost 2019 Mar 28. Epub 2019 Mar 28.

K. G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø.

Background: It remains uncertain whether activation of the complement system, assessed by the soluble terminal C5b-9 complement complex (plasma TCC), is associated with future risk of incident venous thromboembolism (VTE).

Objectives: To investigate the association between plasma levels of TCC and future risk of incident VTE in a nested case-control study, and to explore genetic variants associated with TCC using protein quantitative trait loci (pQTL) analysis of exome sequencing data.

Methods: We sampled 415 VTE cases and 848 age- and sex-matched controls from a population-based cohort, the Tromsø study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14438DOI Listing
March 2019
2 Reads

Studies into Prekallikrein Activation Pave the Way for New Avenues of Antithrombotic Research.

J Thromb Haemost 2019 Mar 27. Epub 2019 Mar 27.

Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY.

In recent years, the contact pathway of coagulation has received increased attention as it appears to be more relevant to pathologic thrombosis than to normal hemostasis. In this pathway, factor XII (FXII) becomes activated upon binding to a negatively charged surface [1] and then activates factor XI (FXI) [2, 3], which in turn activates factor IX [4]. In an additional positive feedback loop, activated FXII (FXIIa) activates prekallikrein (PK) [5], which activates additional FXIIa [6]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14435DOI Listing

GATA-1 a potential novel biomarker for the differentiation of essential thrombocythaemia and myelofibrosis.

J Thromb Haemost 2019 Mar 19. Epub 2019 Mar 19.

School of Life Sciences, University of Lincoln.

Background: The BCR-ABL negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia (ET) and myelofibrosis (MF) are characterised by mutations in JAK2, CALR or MPL. However, a yet unknown factor drives the precise disease phenotype. The haematopoietic transcription factor GATA-1 and its downstream targets NFE2 and FLI1 are responsible for determining erythroid and megakaryocyte lineages during haematopoietic stem cell differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14433DOI Listing
March 2019
6 Reads

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.

J Thromb Haemost 2019 Mar 18. Epub 2019 Mar 18.

Bioverativ, a Sanofi Company, Waltham, MA.

Background: Activated factor VIII (FVIIIa) mimetic bispecific antibodies (bsAbs) aim to enable prophylactic treatment of hemophilia A patients with and without inhibitors. With different mechanisms of action, benchmarking their activity against FVIII to determine efficacious yet safe dosage is difficult.

Objective: To compare the activities of sequence identical emicizumab (SI-Emi) and another bsAb, BS-027125, to recombinant FVIII (rFVIII) using clinical and non-clinical assays and to evaluate our ability to assign a FVIII-equivalent value to bsAbs and implications thereof. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14430DOI Listing
March 2019
1 Read

Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.

J Thromb Haemost 2019 Mar 19. Epub 2019 Mar 19.

Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.

Introduction: Spurious hemolysis of samples is the leading cause of interference in coagulation testing and was described to interfere in fibrinolysis assays. The influence of hemolysis on the procarboxypeptidase U (proCPU) system is not known.

Methods: By means of spiking of hemolysate in pooled normal plasma, the effect of hemolysis on CPU, proCPU and functional clot lysis assays was assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14432DOI Listing

Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis.

J Thromb Haemost 2019 Mar 18. Epub 2019 Mar 18.

Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona (FE), Italy.

Background: Early administration of P2Y12-receptor inhibitors is recommended in all patients with acute coronary syndrome undergoing invasive management, with the aim to achieve the fastest and most effective platelet inhibition. Several trials investigated alternative methods of P2Y12-receptor inhibitor administration (mainly chewed or crushed) aimed at ensuring faster and higher platelet inhibition. Thus, we decided to perform a systematic review and meta-analysis analyzing efficacy and safety of alternative P2Y12-receptor inhibitor administration strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14434DOI Listing
March 2019
3 Reads

Factor XIII: what does it look like?

J Thromb Haemost 2019 Mar 18. Epub 2019 Mar 18.

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Coagulation factor XIII (FXIII) is a stepchild among clotting factors. As opposed to all other zymogenic clotting factors, it is not the precursor of a proteolytic enzyme but of a transglutaminase. It is of tetrameric structure consisting of two types of subunits (FXIII-A B ). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14431DOI Listing
March 2019
1 Read

First description of an IgM monoclonal antibody causing α β integrin activation and acquired Glanzmann thrombasthenia associated with macrothrombocytopenia.

J Thromb Haemost 2019 Mar 13. Epub 2019 Mar 13.

Reference Center for Platelet Disorders, Pessac, France.

Essentials Acquired Glanzmann thrombasthenia (GT) is generally caused by anti-α β autoantibodies. We report the case of a man with an acquired GT phenotype associated with macrothrombocytopenia. Perturbed platelet function were associated with an activating anti-α β IgM autoantibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14424DOI Listing
March 2019
3 Reads

Activated protein C inhibits lipopolysaccharide-mediated acetylation and secretion of high-mobility group box 1 in endothelial cells.

J Thromb Haemost 2019 Mar 13. Epub 2019 Mar 13.

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Essentials APC elicits cytoprotective responses in endothelial cells via EPCR-dependent cleavage of PAR1. APC inhibits LPS-mediated translocation and extracellular secretion of HMGB1 in endothelial cells. Signaling activity of APC inhibits LPS-mediated acetylation of HMGB1 by epigenetic mechanisms. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14425
Publisher Site
http://dx.doi.org/10.1111/jth.14425DOI Listing
March 2019
2 Reads

In vitro phosphorylation of von Willebrand factor by FAM20c enhances its ability to support platelet adhesion.

J Thromb Haemost 2019 Mar 12. Epub 2019 Mar 12.

Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

Essentials Platelet adhesion to von Willebrand factor (VWF) is critical for hemostasis and thrombosis. Whether VWF can undergo phosphorylation is unknown. Family with sequence similarity 20 kinase phosphorylates VWF A2 domain at S1517 and S1613. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14426DOI Listing
March 2019
1 Read

Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation.

J Thromb Haemost 2019 Mar 12. Epub 2019 Mar 12.

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

Essentials The mechanism of antiphospholipid antibodies (aPL) production remains unclear. We investigated lymphocyte subset, single nucleotide polymorphisms (SNP), and aPL-producing cells. The increase of circulating plasmablasts was associated with type I interferon upregulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14427DOI Listing
March 2019
2 Reads

Reducing the hospital burden associated with the treatment of pulmonary embolism.

J Thromb Haemost 2019 Mar 9. Epub 2019 Mar 9.

Department of Emergency Medicine, Stony Brook School of Medicine, Stony Brook, NY, USA.

Pulmonary embolism (PE) is the most feared clinical presentation of venous thromboembolism (VTE). Patients with PE have traditionally been treated in hospital; however, many are at low risk of adverse outcomes and current guidelines suggest outpatient treatment as an option. Outpatient treatment of PE offers several advantages, including reduced risk of hospital-acquired conditions and potential cost savings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14423DOI Listing
March 2019
1 Read

Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: A systematic review and Meta-analysis: Comment.

J Thromb Haemost 2019 Mar 8. Epub 2019 Mar 8.

CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, France.

In a recent article (1), Elsebaie MA et al. performed a systematic review on direct oral anticoagulants (DOACs) use in venous thromboembolism (VTE) and thrombophilia. In the subgroup of antiphospholipid syndrome (APS) patients and after exclusion of recurrent arterial events, the meta-analysis of six studies (Re-COVER, RE-COVER II, RE-MEDY, EINSTEIN-DVT, EINSTEIN-PE, HOKUSAI VTE, RAPS, TRAPS) suggested that no statistically significant differences were observed between DOACs and warfarin for prevention of recurrent VTE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14422DOI Listing
March 2019
3 Reads

What the Neighbours Say.

Authors:

J Thromb Haemost 2019 Apr 7;17(4):563. Epub 2019 Mar 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14416DOI Listing

Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study.

J Thromb Haemost 2019 Feb 25. Epub 2019 Feb 25.

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

Essentials Ceruloplasmin (CP) is an acute-phase reactant and a potential biomarker of atherothrombotic risk. We assessed associations between CP and venous thromboembolism (VTE) risk in 9933 individuals. Higher circulating CP but not CP-related genes were associated with greater incident VTE rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14420DOI Listing
February 2019

Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfb-positive hematopoietic cells.

J Thromb Haemost 2019 Feb 23. Epub 2019 Feb 23.

University of Bordeaux, UMR 1034, INSERM, Biology of Cardiovascular Diseases, Pessac, F-33600, France.

Essentials To reliably study the respective roles of blood and endothelial cells in hemostasis, mouse models with a strong and specific endothelial expression of the Cre recombinase are needed. Using mT/mG reporter mice and conditional JAK2 mice, we compared Pdgfb-iCreERT2 and Cdh5(PAC)-CreERT2 with well-characterized Tie2-Cre mice. Comparison of recombination efficiency and specificity towards blood lineage reveals major differences between endothelial transgenic mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14417DOI Listing
February 2019
2 Reads

Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI.

J Thromb Haemost 2019 Feb 23. Epub 2019 Feb 23.

Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, UK.

Essentials Zymogen PK is activated to PKa and cleaves substrates kininogen and FXII contributing to bradykinin generation. Monomeric PKa and dimeric homologue FXI utilize the N-terminal apple domains to recruit substrates. A high-resolution 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14418DOI Listing
February 2019
1 Read

The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test.

J Thromb Haemost 2019 Feb 23. Epub 2019 Feb 23.

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Essentials The diagnosis of ITP is based on a platelet count < 100 × 10  L and exclusion of other causes. There are no standard tests or biomarkers to diagnose ITP. The sensitivity of platelet autoantibody testing is low (53%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14419DOI Listing
February 2019

Platelets retain inducible alpha granule secretion by P-selectin expression but exhibit mechanical dysfunction during trauma-induced coagulopathy.

J Thromb Haemost 2019 Feb 19. Epub 2019 Feb 19.

Department of Emergency Medicine, University of Washington, Seattle, WA, USA.

Essentials Platelets in trauma-induced coagulopathy (TIC) are impaired, but the mechanism is not known. We performed comprehensive longitudinal platelet function testing in trauma patient samples. Platelets in TIC are widely impaired early after injury, but platelet activatability is intact. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14414DOI Listing
February 2019
2 Reads

Factor XI and recurrent venous thrombosis: an observational cohort study.

J Thromb Haemost 2019 Feb 19. Epub 2019 Feb 19.

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Essentials Factor XI is a potential target for anticoagulation. The association between factor XI and venous thrombosis recurrence was tested in a cohort study. Low factor XI was associated with reduced risk of recurrent venous thrombosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14415DOI Listing
February 2019
2 Reads

Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.

J Thromb Haemost 2019 Feb 17. Epub 2019 Feb 17.

Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

Essentials Factor XIII is a heterotetramer with 2 catalytic A subunits and 2 non-catalytic B subunits. Structure of active and inactive factor XIII was studied with atomic force microscopy. Inactive factor XIII is made of an A globule and 2 flexible B subunits extending from it. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14412DOI Listing
February 2019
8 Reads

High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome.

J Thromb Haemost 2019 Feb 18. Epub 2019 Feb 18.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

Essentials Spontaneous HIT syndrome clinically/serologically resembles HIT but without proximate heparin. Rarely, spontaneous HIT syndrome complicates total knee arthroplasty surgery. Mesenteric vein thrombosis is a rare presentation of spontaneous HIT syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14411DOI Listing
February 2019
5 Reads

Effect of prothrombotic genotypes on the risk of venous thromboembolism in patients with and without ischemic stroke. The Tromsø Study.

J Thromb Haemost 2019 Feb 18. Epub 2019 Feb 18.

K. G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.

Essentials Prothrombotic genotypes may agument the risk of venous thromboembolism (VTE) after ischemic stroke. We studied this effect in a case-cohort study using a genetic risk score. In stroke patients, a one-category increase in the genetic risk score was associated with a 50% higher relative risk of VTE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14410DOI Listing
February 2019
1 Read

Intraoperative infusion of noradrenaline improves platelet aggregation in patients undergoing coronary artery bypass grafting: a randomized controlled trial.

J Thromb Haemost 2019 Apr 11;17(4):657-665. Epub 2019 Mar 11.

Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Essentials Strategies to improve platelet function may reduce excessive bleeding during cardiac surgery. Patients were randomized to standard care or standard care + noradrenaline infusion. Low-dose noradrenaline improved intraoperative platelet aggregation and clot formation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14408DOI Listing

Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura.

J Thromb Haemost 2019 Apr 6;17(4):666-669. Epub 2019 Mar 6.

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.

Essentials Congenital thrombotic thrombocytopenic purpura (cTTP) is a very rare thrombotic microangiopathy. Its rarity and great phenotype heterogeneity may account for misdiagnosis. We report the history of a middle-aged woman with cTTP, misdiagnosed until adulthood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14409DOI Listing
April 2019
1 Read

Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols.

J Thromb Haemost 2019 Apr 13;17(4):596-606. Epub 2019 Mar 13.

Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.

Essentials Biological activity of human neutrophil peptide (HNP)-1 in hemostasis under physiological conditions is not fully understood. HNP-1 inhibits the adhesion/aggregation of murine platelets on a fibrillar collagen surface or an activated endothelial cell surface under flow. The anti-adhesion activity appears to depend on the terminal free thiols of HNP-1, which may inhibit VWF-VWF lateral associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14407DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443439PMC
April 2019
4 Reads

Factor VIIa-induced interaction with integrin controls the release of tissue factor on extracellular vesicles from endothelial cells.

J Thromb Haemost 2019 Apr 1;17(4):627-634. Epub 2019 Mar 1.

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.

Essentials Prothrombotic extracellular vesicles (EV) carry agonist pathway-specific proteomes Agonists for protease activated receptor (PAR) 2 signaling have distinct effects on EV composition PAR2 signaling rapidly generates prothrombotic EV and slowly EV with inactive tissue factor (TF) FVIIa integrin ligation restricts TF incorporation into EV from endothelial cells SUMMARY: Background Cell injury signal-induced activation and release of tissue factor (TF) on extracellular vesicles (EVs) from immune and vessel wall cells propagate local and systemic coagulation initiation. TF trafficking and release on EVs occurs in concert with the release of cell adhesion receptors, including integrin β heterodimers, which control trafficking of the TF-activated factor VII (FVIIa) complex. Activation of the TF signaling partner, protease-activated receptor (PAR) 2, also triggers TF release on integrin β EVs from endothelial cells, but the physiological signals for PAR2-dependent EV generation at the vascular interface remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14406DOI Listing
April 2019
6 Reads

New functional test for the TFPIα cofactor activity of Protein S working in synergy with FV-Short.

J Thromb Haemost 2019 Apr 11;17(4):585-595. Epub 2019 Mar 11.

Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.

Essentials Protein S and FV-Short are synergistic cofactors to Tissue Factor Pathway Inhibitor α (TFPIα). An assay for the TFPIα synergistic cofactor activity of protein S with FV-Short was developed. The assay was specific for the synergistic TFPIα-cofactor activity of free protein S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14405DOI Listing
April 2019
6 Reads